Survival Expectations in Metastatic Castration-Resistant Prostate Cancer

Introduction to Survival Data

Patients with metastatic castration-resistant prostate cancer have a median survival of less than 2 years, but with modern therapies, many patients now live 5 or more years, according to the American Urological Association 1, 2

In the pre-2004 era, median survival was less than 2 years, with treatments administered solely for palliation, as noted by the American College of Radiology 3, 2, 4
During the docetaxel era (2004-2010), median survival improved to 16.3-19.2 months with docetaxel-based chemotherapy, based on evidence from the European Society for Medical Oncology 5

Abiraterone demonstrates similar survival benefits in chemotherapy-naïve populations, according to the American Urological Association 6
Docetaxel (3-weekly) has a median survival of 19.2 months in the TAX327 trial, as reported by the European Society for Medical Oncology 5
Sipuleucel-T has a median overall survival of 30.7 months in patients with asymptomatic or minimally symptomatic mCRPC who have not received prior docetaxel or novel hormone therapy, based on guidelines from the National Comprehensive Cancer Network 8

Asymptomatic or minimally symptomatic disease is associated with longer survival, as noted by the American Urological Association 3, 6
Good performance status (ECOG 0-1) is a favorable prognostic factor, according to the National Comprehensive Cancer Network and the American Urological Association 8, 6
Lymph node-only metastases are associated with longer survival compared to bone or visceral metastases, based on evidence from the American Urological Association 6
Visceral metastases, particularly liver, are associated with the highest mortality risk, as reported by the American Urological Association 6
Bone metastases have an intermediate mortality risk, according to the American Urological Association 6

BRCA-positive patients may benefit from PARP inhibitors, potentially extending survival beyond standard therapies, as noted by the European Society for Medical Oncology 7
177Lu-PSMA-617 provides significant survival benefit after progression on ARPI and taxane-based chemotherapy, based on evidence from the European Association of Urology 7

Discontinuing ADT is not recommended, even when adding novel therapies, as maintaining castrate testosterone levels is essential for optimal outcomes, according to the American Urological Association and the European Society for Medical Oncology 9, 7
Delaying treatment transitions can negatively impact overall survival, as noted by the American Urological Association 7
Offering aggressive therapy to poor performance status patients is not recommended, as they should focus on end-of-life care rather than additional systemic therapy, based on guidelines from the American Urological Association 3
Using sipuleucel-T in patients with visceral metastases is not recommended, as benefit has not been demonstrated in this population, according to the National Comprehensive Cancer Network 8

Asymptomatic, chemotherapy-naïve patients with good performance status can expect a median survival of 30-35+ months with modern ARPI therapy, based on evidence from the National Comprehensive Cancer Network and the American Urological Association 8, 1
Patients receiving sequential multiple lines of therapy can often achieve 5+ years of survival, as noted by the American Urological Association 1
Poor performance status or extensive visceral disease is associated with a median survival typically less than 12 months, according to the American College of Radiology and the American Urological Association 3, 4